Skip to main content

Advertisement

SpringerLink
Log in

The evolving role of medical therapy for chronic stable angina

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The management of chronic stable angina has undergone considerable evolution over the past two decades. This article highlights the need for a comprehensive approach to management that includes carefully identifying cardiac risk factors, using therapeutic lifestyle interventions, aggressive, multifaceted medical therapy, and judiciously using myocardial revascularization. For patients whose ischemia cannot be optimally controlled with traditional anti-ischemic agents, a novel antianginal and anti-ischemic agent (ie, ranolazine) has promise in reducing refractory ischemia as add-on therapy. This article discusses the role of coronary artery bypass graft surgery and percutaneous coronary intervention (PCI) in managing chronic stable angina patients and the clinical implications of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive drug Evaluation) trial. The combined use of a “focal” approach (PCI to treat the culprit stenosis) and a “systemic” approach (lifestyle intervention and aggressive pharmacotherapy) may afford the best event-free survival and clinical outcomes in patients with stable angina.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The American Heart Association: Heart Disease and Stroke Statistics—2008 Update. Available at http://www.americanheart.org/presenter.jhtml?identifier=10000015&q=heart+and+stroke+statistical+update+2007. Accessed April 10, 2008.

  2. Gibbons RJ, Abrams J, Chatterjee K, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003, 41:159–168.

    Article  PubMed  Google Scholar 

  3. Fox CS, Evans JC, Larson MG, et al.: Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950–1999: the Framingham Heart Study. Circulation 2004, 110:522–527.

    Article  PubMed  Google Scholar 

  4. Ford ES, Ajani UA, Croft JB, et al.: Explaining the decrease in US deaths from coronary disease, 1980–2000. N Engl J Med 2007, 356:2388–2398.

    Article  PubMed  CAS  Google Scholar 

  5. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004, 110:588–636.

    Article  PubMed  Google Scholar 

  6. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13–20.

    Article  PubMed  Google Scholar 

  7. Mehta SR, Cannon CP, Fox KA, et al.: Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005, 293:2908–2917.

    Article  PubMed  CAS  Google Scholar 

  8. Shaw LJ, Merz CN, Pepine CJ, et al.: The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health—National Heart, Lung, and Blood Institute—sponsored women’s ischemia syndrome evaluation. Circulation 2006, 114:894–904.

    Article  PubMed  Google Scholar 

  9. Fraker TD, Fihn SD: 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007, 50:2264–2274.

    Article  PubMed  Google Scholar 

  10. Gonzales D, Rennard SI, Nides M, et al.: Varenicline, an alpha4-beta2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296:47–55.

    Article  PubMed  CAS  Google Scholar 

  11. Gielen S, Schuler G, Hambrecht R: Exercise training in coronary artery disease and coronary vasomotion. Circulation 2001, 103:e1–e6.

    PubMed  CAS  Google Scholar 

  12. De Lorgeril M, Salen P, Martin JL, et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779–785.

    PubMed  Google Scholar 

  13. Abrams J: Chronic stable angina. N Engl J Med 2005, 352:2524–2533.

    Article  PubMed  CAS  Google Scholar 

  14. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  15. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 244:1383–1389.

  16. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  17. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  18. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  19. Look AHEAD: Action for Health in Diabetes. Available at http://www.LookAHEADstudy.org. Accessed January 2008.

  20. Action to Control Cardiovascular Risk in Diabetes (ACCORD). Available at http://www.accordtrial.org. Accessed January 2008.

  21. Peters RJ, Mehta SR, Fox KA, et al.: Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes. Circulation 2003, 108:1682–1687.

    Article  PubMed  CAS  Google Scholar 

  22. Vatner SF, Baig H, Manders T, et al.: Effects of propranolol on regional myocardial function, electrograms, and blood flow in conscious dogs with myocardial ischemia. J Clin Invest 1977, 60:353–360.

    Article  PubMed  CAS  Google Scholar 

  23. Thadani U: Treatment of stable angina. Curr Opin Cardiol 1999, 14:349–358.

    Article  PubMed  CAS  Google Scholar 

  24. Heindenreich PA, McDonald KM, Hastie T, et al.: Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999, 281:1927–1936.

    Article  Google Scholar 

  25. Pepine CJ, Abrams J, Marks RG, et al.: Characteristics of a contemporary population with angina pectoris. TIDES investigators. Am J Cardiol 1994, 74:226–231.

    Article  PubMed  CAS  Google Scholar 

  26. Mannheimer C, Camici P, Chester MR, et al.: The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory angina. Eur Heart J 2002, 23:355–370.

    Article  PubMed  CAS  Google Scholar 

  27. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [no authors listed]. N Engl J Med 2000, 342:145–153.

  28. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.

    Article  PubMed  CAS  Google Scholar 

  29. Pepine CJ, Nichols WW: The pathophysiology of chronic ischemic heart disease. Clin Cardiol 2007, 30(Suppl I):I4–I9.

    Article  Google Scholar 

  30. Belardinelli L, Shryock JC, Fraser H: The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J Suppl 2006, 8(Suppl A):A10–A13.

    Article  CAS  Google Scholar 

  31. Cairns JA: Ranolazine: augmenting the anti-anginal armamentarium. J Am Coll Cardiol 2006, 48:e1–e3.

    Article  Google Scholar 

  32. Rousseau MF, Pouleur H, Cocco G, et al.: Comparative efficacy of Ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005, 95:311–316.

    Article  PubMed  CAS  Google Scholar 

  33. Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004, 291:309–316.

    Article  PubMed  CAS  Google Scholar 

  34. Stone PH, Gratsiansky NA, Blokhin A, et al.: Antianginal efficacy of ranolazine when added to maximal treatment with a conventional therapy: the efficacy of ranolazine in chronic angina (ERICA) trial. J Am Coll Cardiol 2006, 48:566–575.

    Article  PubMed  CAS  Google Scholar 

  35. Chaitman BR, Skettino SL, Parker JO, et al.: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375–1382.

    Article  PubMed  CAS  Google Scholar 

  36. Anderson JR, Nawarskas JJ: Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev 2005, 13:202–210.

    Article  PubMed  Google Scholar 

  37. Boden WE, Bough EW, Reichman MJ, et al.: Beneficial effects of high dose cardizem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double blind, placebo-controlled cross-over study. Circulation 1985, 71:1197–1205.

    PubMed  CAS  Google Scholar 

  38. Ronnevik PK, Silke B, Ostergaard O: Felodipine in addition to beta-adrenergic blockade for angina pectoris. A multicentre, randomized, placebo-controlled trial. Eur Heart J 1995, 16:1535–1541.

    PubMed  CAS  Google Scholar 

  39. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndrome. The MERLIN-TIMI 36 randomized trial. JAMA 2007, 297:1775–1783.

    Article  PubMed  CAS  Google Scholar 

  40. Scirica BM, Morrow DA, Hod H, et al.: Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-elevation acute coronary syndromes. Circulation 2007, 116:1647–1652.

    Article  PubMed  CAS  Google Scholar 

  41. Serruys PW, Unger F, Sousa JE, et al.: Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001, 344:1117–1124.

    Article  PubMed  CAS  Google Scholar 

  42. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. JAMA 1997, 277:715–721.

  43. Magee MF, Isley WL: Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006, 97:20G–30G. Available at http://www.bari2d.org. Accessed January 2008.

    Article  PubMed  Google Scholar 

  44. Hoffman SN, Tenbrook JA, Wolf MP, et al.: A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one-to eight-year outcomes. J Am Coll Cardiol 2003, 41:1293–1304.

    Article  PubMed  Google Scholar 

  45. Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial. Available at http://www.mssm.edu/cvi/freedom_trial/. Accessed January 2008.

  46. Holubkov R, Laskey WK, Haviland A, et al.: Angina 1 year after percutaneous coronary intervention: a report of the NHLBI dynamic registry. Am Heart J 2002, 144:826–833.

    PubMed  Google Scholar 

  47. Alderman EL, Kip KE, Whitlow PL, et al.: Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2004, 44:766–774.

    Article  PubMed  Google Scholar 

  48. Katritsis DG, Ioannidis JP: Percutaneous coronary intervention versus conservative therapy in non-acute coronary artery disease: a meta-analysis. Circulation 2005, 111:2906–2912.

    Article  PubMed  Google Scholar 

  49. Boden WE, O’Rourke RA, Teo KK, et al.: Optimal medical therapy with or without PCI in stable coronary disease. N Engl J Med 2007, 35:1503–1516.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY, 14203, USA

    William E. Boden

Authors
  1. Freidy Eid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William E. Boden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William E. Boden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eid, F., Boden, W.E. The evolving role of medical therapy for chronic stable angina. Curr Cardiol Rep 10, 263–271 (2008). https://doi.org/10.1007/s11886-008-0044-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-008-0044-y

Keywords

Search

Navigation